Filing Details
- Accession Number:
- 0000950170-24-038731
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-03-29 16:52:39
- Reporting Period:
- 2024-03-27
- Accepted Time:
- 2024-03-29 16:52:39
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1650648 | 4D Molecular Therapeutics Inc. | FDMT | Biological Products, (No Disgnostic Substances) (2836) | 473506994 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1920738 | Scott Bizily | C/O 4D Molecular Therapeutics, Inc. 5858 Horton Street #455 Emeryville CA 94608 | Chief Legal Officer | No | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2024-03-27 | 4,342 | $25.98 | 6,079 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2024-03-27 | 1,491 | $25.98 | 7,570 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2024-03-27 | 5,833 | $35.04 | 1,737 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right To Buy) | Disposition | 2024-03-27 | 4,342 | $0.00 | 4,342 | $25.98 |
| Common Stock | Stock Option (Right To Buy) | Disposition | 2024-03-27 | 1,491 | $0.00 | 1,491 | $25.98 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 55,658 | 2031-09-30 | No | 4 | M | Direct | |
| 54,167 | 2031-09-30 | No | 4 | M | Direct |
Footnotes
- Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023.
- The transaction was executed in multiple trades in prices ranging from $35.00 to $35.20, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- 25% of the shares subject to the option vest on the first anniversary measured from October 1, 2021 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest in thirty-six (36) successive and equal monthly installments thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.
Billionaire Hedge Funds
